Mechanisms
- Enzymatic inactivation: β-lactamases (including ESBLs and carbapenemases such as NDM-1, KPC and OXA-48), aminoglycoside-modifying enzymes and chloramphenicol acetyltransferase.
- Target change: altered penicillin-binding protein PBP2a (mecA gene) in MRSA, D-Ala-D-Lac cell wall precursors in VRE, gyrase mutations for quinolones, rpoB mutations for rifampicin, and ribosomal methylation (erm) for macrolides.
- Reduced entry: loss of outer-membrane porins, especially in Pseudomonas and Enterobacterales.
- Efflux pumps push out tetracyclines, fluoroquinolones and macrolides.
- Bypass pathways: altered enzymes that the drug no longer blocks (e.g. sulfonamide-resistant dihydropteroate synthase).